China Cell Therapy Party On: $500m+ Raised In JW IPO, Other Rounds
CAR-T Developer Plans US, Europe Expansion
It's been a big week for cell therapy developers in China with well over $500m raised through an IPO and large new funding rounds for several other ventures.
You may also be interested in...
Gracell and FutureGen and NovaRock and Flame partner in Claudin 18.2 antibody R&D for cancer. Plus deals involving HDT Bio/Quratis, Pfizer China/Ferring and Antengene/MindRank AI.
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.